Quick Answer
Prelude Therapeutics Inc reported Total Assets of $141.31 million for fiscal year 2025.
Prelude Therapeutics Inc Total Assets — Annual History
| Fiscal Year | Total Assets | YoY Change |
|---|---|---|
| 2025 | $141.31M | -19.5% |
| 2024 | $175.51M | -36.8% |
| 2023 | $277.67M | +25.9% |
| 2022 | $220.50M | -27.7% |
| 2021 | $305.10M | +36.5% |
| 2020 | $223.59M | +922.3% |
| 2019 | $21.87M | — |
Quarterly Total Assets
| Quarter Ending | Total Assets | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $94.75M | -52.0% | -17.5% |
| June 30, 2025 | $114.92M | -48.8% | -18.6% |
| March 31, 2025 | $141.26M | -42.8% | -19.5% |
| December 31, 2024 | $175.51M | -36.8% | -11.0% |
| September 30, 2024 | $197.22M | -23.7% | -12.1% |
| June 30, 2024 | $224.29M | -20.1% | -9.2% |
| March 31, 2024 | $247.11M | +24.6% | -11.0% |
| December 31, 2023 | $277.67M | +25.9% | +7.4% |
- Prelude Therapeutics Inc showed a decrease of -19.5% in Total Assets compared to the prior fiscal year.
- Over the 2019–2025 period, Prelude Therapeutics Inc’s total assets has grown by 546.1% (from $21.87 million to $141.31 million).
- The most recent figure is from Prelude Therapeutics Inc’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 10, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: